

CIBUS®

The Future of Breeding™



C I B U S[®]

Cautionary Statements Regarding Forward Looking Information

This presentation contains forward looking statements based on current assumptions and forecasts made by Cibus Management

Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual results, financial situations, development or performance of the company and the estimates given here. These factors include those discussed in Cibus' public reports which are available at Cibus.com.

Except as provided by law, this company assumes no obligations whatsoever to update these forward-looking statements or to conform them to future events or developments.

See slide 18 for detailed term definitions, data sources & assumptions.

Experienced Management Team



ROTY RIGGS
CEO, CHAIRMAN
CO-FOUNDER

ROYALTY Biomatrix
PHARMA Sugen
FibroGen Syntax
C I B U S



Peter Beetham, PhD
COO, PRESIDENT
CO-FOUNDER



Greg Gocal, PhD EVP, CHIEF SCIENTIFIC OFFICER, CO-FOUNDER



Noel Sauer, PhD SVP, HEAD OF R&D




Wade King, MD
CHIEF FINANCIAL
OFFICER



Steve Berreth, JD

Background: Productivity Trait Business

Productivity Traits are "Genetic Products" that Improve Yields with Lower Costs



Yield Drivers

Seeds (Germplasm) Improvements

Productivity Traits

Chemicals



Chemicals refers to Insecticides & Fungicides for the crop protection chemicals business. Est 2020 Revenues ~\$40 Billion with 20 to 25% Operating margin.



Trait Business: Trait IP Licensed to Seed Co's for Royalties

Royalties are Paid on Bags of Seeds (or Acres) where Traits are Used



Bt Trait is an Example of How Productivity Traits Work

Bt Protein Trait is based on a "Bt Protein" that make Plants Toxic to Specific Pest

"Bt" Trait Fees are Paid on a "Crop-by-Crop" Acres



3	>300 MM Tra	ait Fee Acres
	The Bt Trait Market	
	Trait Fees (Per Acre)	\$10-\$20
	Trait Fee Acres	> 300 мм
	Annual Trait Fees	~\$4 B

Trait Fees Paid Per Acre (Based on Bags of Seeds Sold)

\$2.6 B

\$0.5 B

\$0.7 B

Annual Trait Fees (Crop by Crop 2020 est.)

Bt Trait is presented as an example. It is not owned by Cibus. It is owned and licensed by several seed companies


Note: See slide 18 for term definitions, data sources &

^{*} Trait Fee acreage information are 2020 estimates based on data from Agbioinvestor, US Gov., BCG & 3rd party consultants. Traits are predominantly GMO traits in North & South America.



Trait Development has Scale & Speed Limitations


Conventional Trait Development averages: 12 to 15 Years (or Decades)
GMO Trait Development (Breeding!) Averages ~16.5 Years, \$115 Million



Cibus' *Trait Machine™ Process* Changes the Game

Proprietary Standardized End-to-End Semi-Automatic Breeding System


Scientific, Timebound, and Reproducible Breeding Process.



Changes Both Trait Development & Speed to Market

Development: Enables Product Prototypes

Commercialization: Traits are Edited Directly into Each Customers Elite Germplasm.



Sclerotinia Provides an Example of a Cibus Trait Timeline

Using Canola Trait Machine Platform:

Trait Development is a Fraction of the Time (and Cost!) of Conventional Breeding

Sclerotinia Trait is a Real-Time Example of the Timeline for "Trait Machine" Trait Development



Canola Timeline

Molecular Discovery Done

Initiate Editing (1st MOA) 2019

Green House Data 2022-23


Field Validation (est.) 2023-24

Royalty Market ~\$270мм

Note: See slide 18 for term definitions, data sources & assumptions. In 2019, we did the 1st Edit .in the 1st MOA for Sclerotinia.

Industry Close to New Regulatory Standards

Recent EU Proposal: Regulate Cibus Traits as "Conventional-Like"



Gene Editing is One of the Only **Tools that Can Provide** the Speed & Scale to **Address Challenges** of Climate.

Note: Cibus traits are developed without integrating foreign DNA in the process or product. in key target markets including the United States, the new gene editing regulations are specifically separating Cibus traits from GMO (Genetically Modified Organisms) and regulating Cibus Traits similarly to traits from conventional breeding.

Our Business

Trait Developer: Licensing, Royalties

Core Technology: Trait Machine Process



TURN TO

Seed Companies

Seed Co's Compete on Traits that Improve Productivity.

Farmers pay Trait Fees.

WHO TURN TO

Trait Developers

License Trait IP to Seed Co's Paid Royalties by Seed Co's



Cibus has a Pipeline of 6 Productivity Traits

3 Traits are Developed & Transferring, 2 Traits are Advanced

Developed - Transferring

Pod Shatter Reduction

- Canola, Winter Oilseed Rape
- Est Market 28 million acres

HT1

- Rice
- Est Market 4 million acres

HT3

- Rice
- Est Market 4 million acres

Advanced

Sclerotinia Resistance

- Canola, Winter Oilseed Rape, Soybean
- Est. Market 80 million acres

HT2

- Canola, Winter Oilseed Rape, Soybean
- Est. Market 94 million acres

Initiating

Nitrogen Use Efficiency

- Canola, Winter Oilseed Rape, Rice
- Est. Market 50 million acres



Trait Business is Crop-by-Crop

Although Traits are Multi-Crop, the Trait Business is Crop Specific

Cibus' 3 Initial Crop Platforms







Note: See slide 18 for term definitions, data sources & assumptions.

^{*} Soybean Platform is not operational. It is expected to be operational in H2 2023.

Trait Machine Operational means a validated Trait Machine Process has been established.

⁻ Market acres are for North America, South America, Europe & Australia

Cibus' "Trait Machine" Facility is Key to its Business

Trait Machine Process Accelerates Speed to Market for Developed Traits








Note: See slide 18 for term definitions, data sources & assumptions Cibus' Rapid Trait Development System is often referred to as *RTDS*® or the **Trait Machine**™.



Guidance: Royalty Markets for Cibus' Trait Pipeline

Trait Market Estimates for Initial Traits in Canola, Rice & Soybean

Initial 3 Crops and 5 Traits, Est. Royalty Mkt ~ \$1.6 B



Guidance: Operational Milestones 2H 2023

Soybean Trait Machine Platform Expected in 2H 2023, Lead Customer GDM

Advancing New Traits and Commercialization (Customers!) in Canola and Rice

- 1) Canola/WOSR (50 MM Acres)
 - a) ~ Five PSR Transfers in 2H 2023
 - b) Green House/Field Data:
 - Sclerotinia (H2 2023)
 - HT2 (H2 2023)
 - c) Initiate Edits:
 - Nitrogen Use Efficiency (H2 2023)



✓ Trait Machine Facility "Oberlin" Operational, July 2023

√ 1st Trait Transfers
Canola & Rice

- 2) Soybean (200 MM Acres)
 - a) Trait Machine Operational (H2 2023)
 - b) Initiate Edits: H2 2023
- 3) Commercial
 - a) Increase in # of Collaborations
 - Rice: Expanding Customers
 - Expanded Collaborations

- Note: See slide 18 for term definitions, data sources & assumptions.
- Soybean platform is not operational yet. It is projected to be operational in 2H 2023. Estimated.

Disclaimer

Securities Law Matters

This presentation has been prepared by Cibus Global, LLC (the "Company"), and the Company is responsible for its contents. It shall not constitute an offer, nor a solicitation of an offer, of the sale or purchase of securities, nor shall any securities of the Company be offered or sold, in any jurisdiction in which such an offer, solicitation or sale would be unlawful. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the transactions contemplated hereby or determined if this presentation is truthful or complete. Any representation to the contrary is a criminal offense.

Industry and Market Data

Information about market and industry statistics contained in this presentation is included based on information available to the Company that it believes is accurate in all material respects. It is generally based on academic and other publications that are not produced for purposes of securities offerings or economic analysis. The Company has not reviewed or included data from all sources, and the Company cannot assure potential investors of the accuracy or completeness of the data included in this presentation. Forecasts and other forward-looking information obtained from these sources, including estimates of future market size, revenue and market acceptance of products and services, are subject to the same qualifications and the additional uncertainties accompanying any forward-looking statements.

Acreage Data

This presentation has 2 available acreage calculations: TAM-Total Trait Fee Acres and Trait Fees Acres. These are based on the company's estimate of total hybrid acres available in: North America, South America & Europe for each crop. European acres are not currently Trait Fee. These acres depend on a favorable outcome of the current EU Parliamentary process. They are shown to show the potential increase in available acres if the EU were to pass the proposed legislation. The EU is expected to advance its legislative process for its proposed legislation.

Intellectual Property

"Cibus," "RTDS," "Rapid Trait Development System," "FALCO," "SU Canola," "Nucelis," "ASAP," "A Different Breed," "Trait Machine," "Inspired by Nature," "Driving Sustainable Agriculture," "Reshaping Crop Protection," "Reinventing Trait Development", "Timebound & Predictable", "Driving Trait & Breeding Innovation", "Future of Breeding", the Cibus logo and other trademarks or service marks of Cibus appearing in this presentation are the property of Cibus.

Trade names, trademarks and service marks of other companies that appear are the property of their respective holders and do not imply a relationship with, or endorsement or sponsorship of us, by these other companies. Solely for convenience, trademarks and trade names in this presentation appear without the ™ and ® symbols, but any such failure to appear should not be construed as indicating that their respective owners will not assert their rights with respect thereto. Cibus has over 400 patents issued or filed.

- 1. Developed means validated field trials (Canola PSR, rice HT1, HT3); Advanced development means editing process underway with known edit targets.
- 2. Bt refers to Bacillus thuringiensis that is a species of bacteria that lives in soil
- 3. HT1, HT2 & HT3 refer to up 3 different herbicide tolerance traits
- 4. Total Market Acres and Trait Fee Acres are company estimates based on industry sources. There can be no assurance that Trait Fee Acres can be achieved.
- 5. Trait Machine Platforms are operational in canola and rice. Soybean is expected to be operational in H2 2023.
- 6 Trait Royalty Market is determined by multiplying the Est. Trait Fee Acres by the Est. Trait Fees for a specific Cibus trait in a specific geography or geographies.
- 7 Shipping means traits are transferred to customers in a customer's elite germplasm.
- 8 MOA refers single mode of action for a complex trait.
- 9. Complex traits refers to traits consisting of multiple modes of action. Greenhouse confirmation of a complex trait may refer to a single MOA or Multiple MOA's.
- 10. Initiate Edits means that the editing process has begun for the trait in the specific
- 11. Greenhouse Data means greenhouse confirmation for a single mode action or multiple modes of action for a trait.
- 12. Trait Machine Operational means a validated Trait Machine Process established 3rd Party Data
- 13. Trait Fee information are 2020 estimates based on data from Agbioinvestor, US Gov., BCG & 3rd party consultants. Traits are predominantly GMO traits in North & South America.

Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding the benefits of the merger, Cibus, Inc.'s ("Cibus") operational and financial performance, and Cibus' strategy, future operations, prospects and plans, are forward-looking statements. Forward-looking statements may be identified by words such as "anticipate," "believe," "intend", "expect," "plan," "scheduled," "could," "would" and "will," or the negative of these and similar expressions. These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. There are many factors that could cause Cibus' actual results, level of activity, performance or achievements to differ materially from those expressed or implied by forwardlooking statements, including factors related to: (i) risks associated with the possible failure to realize certain anticipated benefits of the transactions contemplated by the merger (the "Transactions"), including with respect to future financial and operating results; (ii) the effect of the completion of the Transactions on Cibus' business relationships, operating results and business generally; (iii) the outcome of any litigation related to the merger agreement or Transactions; (iv) competitive responses to the Transactions and changes in expected or existing competition; (v) challenges to Cibus' intellectual property protection and unexpected costs associated with defending Cibus' intellectual property rights; (vi) increased or unanticipated time and resources required for Cibus' platform or trait product development efforts; (vii) Cibus' reliance on third parties in connection with its development activities; (viii) Cibus' ability to effectively license its productivity traits and sustainable ingredient products; (ix) the recognition of value in Cibus' products by farmers, and the ability of farmers and processors to work effectively with crops containing Cibus' traits; (x) Cibus' ability to produce highquality plants and seeds cost effectively on a large scale; (xi) Cibus' need for additional funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; (xii) Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover Cibus' corporate and overhead expenses; (xiii) regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; (xiv) Cibus' ability to achieve commercial success; (xv) commodity prices and other market risks facing the agricultural sector; and (xvi) technological developments that could render Cibus' technologies obsolete. In addition to these factors, other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause Cibus' actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forwardlooking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.